Welcome to our dedicated page for Mereo Biopharma SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mereo BioPharma Group plc (NASDAQ: MREO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed with the Securities and Exchange Commission. These filings offer primary-source information on Mereo’s financial condition, clinical development updates, and material corporate events.
Mereo’s Form 8-K filings, for example, have furnished press releases covering quarterly financial results, cash and cash equivalents, and recent corporate highlights. They also describe key clinical milestones, such as the progress of the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta, Data Monitoring Committee recommendations to proceed to final analysis, and subsequent top-line results. Other 8-K reports outline developments in the company’s pipeline, including partnering activities and regulatory designations for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease.
Through this page, users can follow how Mereo reports its operating performance, research and development spending, and capital structure over time via its SEC submissions. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, 10-Ks or 10-Qs without reading every line.
Investors interested in MREO can use the filings page to monitor material updates on clinical programs, financing, and corporate agreements as they are reported to the SEC. Real-time access, combined with AI-generated explanations, supports efficient review of Mereo BioPharma’s regulatory history and ongoing disclosure record.
Mereo Biopharma Group plc received an amended Schedule 13G/A from Janus Henderson Group plc, reporting that, as of 12/31/2025, it beneficially owned 0 ordinary shares of Mereo and represented 0.0% of the class. Janus Henderson is the ultimate parent of several investment advisers whose client accounts (the Managed Portfolios) may hold Mereo shares, but these portfolios have the right to all dividends and sale proceeds. Janus Henderson and its asset managers report no voting or dispositive power over Mereo shares and disclaim ownership of related economic rights. The filing also notes that none of the Managed Portfolios owns more than five percent of Mereo’s ordinary shares and that any securities were acquired and held in the ordinary course of business, not to change or influence control of the company.
Mereo BioPharma Group plc received an amended Schedule 13G/A (Amendment No. 2) from several Frazier Life Sciences investment entities and their related managing members. The filing states that each reporting person beneficially owns 0 ordinary shares, or 0.0% of the class, of Mereo’s ordinary shares represented by American Depositary Shares as of 12/31/2025. The group also certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the company.
Mereo BioPharma Group plc granted new share options to Chief Scientific Officer John A. Lewicki on February 1, 2026. The awards cover 139,913 share options with a $0.44 exercise price, 46,637 share options with a $1.00 exercise price, and 145,000 share options with a $0.44 exercise price, all over American Depositary Shares.
For the 139,913 options, 25% of the underlying shares vest on February 1, 2027, with the rest vesting in equal monthly installments over the following three years. The 145,000 options vest in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.
Mereo BioPharma Group plc reported that officer Alexandra Hughes-Wilson received new share option grants on February 1, 2026. The awards cover 183,750 American Depositary Shares (ADS) at an exercise price of
For the 183,750-ADS option, 25% vests on
Mereo BioPharma Group plc reported that its General Counsel, Sermon Charles, received new share option awards on February 1, 2026. These are derivative securities giving the right to buy American Depositary Shares (ADS) at preset exercise prices.
The grants include options over 315,750 ADS at $0.44, 105,250 ADS at $1.00, and 295,000 ADS at $0.44, all expiring on February 1, 2036. One grant vests 25% on February 1, 2027 with the remainder vesting monthly over three years, while another vests in substantially equal monthly installments over one year from the grant date. Each ADS represents five ordinary shares.
Mereo BioPharma Group plc reported that Chief Executive Officer and director Denise Scots-Knight received new stock option awards on February 1, 2026. She was granted options to buy 1,035,000 American Depositary Shares at $0.44, 345,000 at $1.00, and 480,000 at $0.44, all held directly.
For the 1,035,000-share grant, 25% will vest and become exercisable on February 1, 2027, with the balance vesting in equal monthly installments over the following three years. The 480,000-share grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.
Mereo BioPharma Group plc reported that its Chief Financial Officer, Christine Fox, received grants of share options on February 1, 2026. These derivative awards give her the right to buy 315,750 American Depositary Shares at an exercise price of $0.44, 105,250 ADS at $1.00, and 280,000 ADS at $0.44.
For the 315,750-option grant, 25% of the underlying shares vest and become exercisable on February 1, 2027, with the rest vesting in equal monthly installments over the following three years. The 280,000-option grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma.
Mereo BioPharma Group plc updated its liquidity outlook and provided new investor materials. The company reported cash and cash equivalents of $41 million as of December 31, 2025, which it now expects will fund operations to mid-2027, extending its projected cash runway. Mereo also issued a corporate update press release and posted an investor presentation for use at the J.P. Morgan Healthcare Conference and other meetings, which are furnished as exhibits and not deemed filed under U.S. securities laws.
Mereo BioPharma Group plc received a Schedule 13G filing showing that funds associated with EcoR1 Capital and its principal Oleg Nodelman beneficially own 74,500,000 Ordinary Shares, equal to 9.4% of the outstanding Ordinary Shares. These holdings are held through 14,900,000 American Depositary Shares, each ADS representing 5 Ordinary Shares.
Within this total, EcoR1 Capital Fund Qualified, L.P. is reported as beneficially owning 69,802,840 Ordinary Shares, or 8.8% of the class, through 13,960,568 ADSs. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company. The reporting persons also formally disclaim group status and beneficial ownership beyond their pecuniary interest.
Mereo BioPharma Group plc received a Schedule 13G filing from investment firm 683 Capital and related parties reporting a significant passive stake. As of January 6, 2026, 683 Capital Partners, LP beneficially owned 65,083,815 ordinary shares, represented by 13,016,763 American Depositary Shares (ADS), which equals about 8.18% of the ordinary shares.
The percentage is based on 795,658,504 ordinary shares outstanding as of November 7, 2025. 683 Capital Management, LLC, as investment manager, and Ari Zweiman, as managing member, may each be deemed to share beneficial ownership. The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Mereo BioPharma.